Aegis Capital
Aegis Capital Corp. is a New York-based broker-dealer that provides wealth management and investment banking services. Its equity research covers a limited number of companies, most of which are also investment banking clients.
Activity24M
RatingsPrice targetsKey figures
- Stocks covered
- 112M
- Actions
- 112M
- Ratings / Price targets
- 1 / 0
- Buy-rated
- 100%of 1 rated
- On record
- Jul 2012 – Oct 2025
Overview
As of 2026, Rommel Dionisio heads the research team, which covers healthcare, biotechnology, medical devices, technology and emerging growth companies. As of April 2026, about 96% of rated stocks had a Buy rating, and 77% of the companies with that rating were investment banking clients.
Robert Eide founded Aegis in New York in 1984. The firm provides brokerage, wealth management, investment banking and equity research services to private clients, institutions and corporations. Regulators have sanctioned it several times: FINRA fined it $950,000 in 2015 over unregistered penny-stock sales, the SEC and FINRA imposed penalties totaling $1.3 million in 2018 for anti-money-laundering failures, and FINRA fined it $1.05 million in 2021 for failures to supervise excessive trading.
Milestones
- 1984
Founded in New York by Robert Eide
- 2015
FINRA fines firm $950,000 over unregistered penny-stock sales
- 2018
Pays $1.3 million to SEC and FINRA over AML failures
- 2021
FINRA fines firm $1.05 million over excessive-trading supervision
Firm facts
- Legal name
- Aegis Capital Corp.
- Type
- Boutique
- Founded
- 1984
- Headquarters
- New York, United States
- Founder and Chief Executive Officer
- Robert Eide
- Rating scale
- BuyHoldSell12–18 months
- Also filed as
- Aegis
- Website
- aegiscapcorp.com
Research philosophy
Our research philosophy is built on intellectual independence, rigorous financial analysis, and a commitment to identifying opportunities that may be overlooked or misunderstood by the broader market.
Aegis says its analysts weigh multiple operating scenarios instead of relying solely on consensus expectations, and that its research extends beyond published reports into ongoing contact with management teams, industry experts and investors.
Rating methodology
Aegis assigns Buy, Hold or Sell ratings based on whether a stock's price adequately reflects the company's prospects over 12–18 months.
Coverage12M
Sectors
Most covered24M
| Stock | Rating | Target |
|---|---|---|
 Sunshine Biopharma, Inc.SBFM | Buy | — |
Recent actions
| Date | Stock | Rating action | Rating |
|---|---|---|---|
| Oct 8, 2025 | Sunshine Biopharma, Inc.SBFM | Reiterate | Buy |
| Dec 5, 2024 | Sunshine Biopharma, Inc.SBFM | Reiterate | Buy |
| May 9, 2023 | STSharps Technology, Inc.STSS | Reiterate | Buy |
| Mar 20, 2023 | GCGigaCloud Technology Inc.GCT | Reiterate | Buy |
| Oct 3, 2022 | GCGigaCloud Technology Inc.GCT | Reiterate | Buy |
| Sep 12, 2022 | EVEvogene Ltd.EVGN | Reiterate | Buy |
| Aug 18, 2022 | DRDarioHealth Corp.DRIO | Reiterate | Buy |
| Aug 8, 2022 | IMImmunic, Inc.IMUX | Reiterate | Buy |
| Jun 14, 2022 | PSPostal Realty Trust, Inc.PSTL | Reiterate | Buy |
| May 16, 2022 | OROramed Pharmaceuticals Inc.ORMP | Reiterate | Buy |
| May 16, 2022 | DRDarioHealth Corp.DRIO | Reiterate | Buy |
| Mar 29, 2022 |  Trevi Therapeutics, Inc.TRVI | Reiterate | Buy |